Reduced TRPC6 mRNA levels in the blood cells of patients with Alzheimer’s disease and mild cognitive...
Reduced TRPC6 mRNA levels in the blood cells of patients with Alzheimer’s disease and mild cognitive impairment
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Transient receptor potential canonical 6 (TRPC6) inhibits β-amyloid (Aβ) production. Hyperforin, the TRPC6 agonist, reduces Aβ levels and improves cognitive performance in Alzheimer’s disease (AD) models. However, it’s unknown whether TRPC6 expression is changed in AD patients. In this case–control study, we measured TRPC6 expression levels in the...
Alternative Titles
Full title
Reduced TRPC6 mRNA levels in the blood cells of patients with Alzheimer’s disease and mild cognitive impairment
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1917962714
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1917962714
Other Identifiers
ISSN
1359-4184
E-ISSN
1476-5578
DOI
10.1038/mp.2017.136
